Kevin Craig, Chief Medical Officer of AtaiBeckley, discusses the current therapeutic landscape for major depressive disorder and therapeutic advances for this hard-to-treat disease. Major depressive disorder (MDD), or depression, remains one of the most urgent and complex challenges in mental health. More than 300 million people1 worldwide live with the condition, but a substantial proportion of these… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers found an unexpected drug could help treat depression. Elsewhere, a new company is… Read More
News round-up for 16 – 20 February by Bruno Quinney, Content Team at DDW. This week in DDW, an unexpected drug could help treat depression. Elsewhere, a new company is set to advance a cerebral palsy therapy. The top stories: Psychedelic drug could help treat depression … Read More
The psychedelic drug dimethyltryptamine (DMT) could help treat depression when combined with psychotherapy, The Guardian has reported. According to preliminary results reported in Nature Medicine, a trial involving 34 patients found that psychotherapy combined with DMT caused a reduction in depressive symptoms, even after the… Read More
AbbVie has agreed to acquire Gilgamesh Pharmaceuticals’ lead asset, bretisilocin (GM-2505), a potential best-in-class compound for the treatment of major depressive disorder (MDD), for up to $1.2 billion. Psychedelic compounds have gained recognition as potential treatments for mental health disorders, because of their demonstrated rapid, robust and… Read More
One or two doses of psilocybin may improve the mental health of cancer patients when accompanied by psychotherapy, a new report suggests. A second new study found that treatment with psilocybin resulted in lasting, positive personality changes in patients with alcohol use disorder. In the… Read More
Dr Anantha Shekhar, MD PhD, Dean of the University of Pittsburgh School of Medicine, explores synapse structure and function in neuroscience and how neuroplasticity can present new opportunities for drug development. With contributions from Rob Houghtaling, MS and John Donello, PhD, Gate Neurosciences. In March 2019, the US FDA approved… Read More
This is the latest episode of the free DDW narrated podcast, titled “The future climate and landscape for drug discovery” which covers three written for Volume 24 – Issue 1, Winter 2022/2023 of DDW. They are called: Pharma’s important climate and What will the… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. In another busy week for drug discovery and development, we have seen the FDA… Read More
News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. In another busy week for drug discovery and development, we have seen the FDA approval of a monoclonal antibody for emergency use in Covid-19, the launch of trials into innovative new treatments for urea cycle disorders… Read More
A novel psychedelic compound, combined with psychological support, will be explored as a potential new treatment for people living with alcohol use disorder (AUD) in a Phase IIa study. The trial uses Beckley Psytech’s lead candidate BPL-003, a short-duration and fast-acting synthetic formulation of psychedelic mebufotenin… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some ground-breaking advances in women’s health this week, with new treatments… Read More
News round-up for 18-22 December by DDW Digital Content Editor Diana Spencer. There have been some ground-breaking advances in women’s health this week, with new treatments for hot flushes and pregnancy sickness, and a discovery that could aid in development of treatments for secondary breast cancer. In… Read More
Results from a Phase II clinical trial indicate that psilocybin may benefit individuals with cancer and major depression. In the study, trial participants treated with psilocybin not only experienced a lessening of depressive symptoms but also spoke highly of the therapy when interviewed at the end… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. The news highlights this week feature a variety of exciting clinical trial… Read More
News round-up for 30 October – 3 November by DDW Editor Reece Armstrong My news highlights this week feature a variety of exciting clinical trial results and launches that are examining therapies for much-needed disease areas, new drug approvals and even a space mission with a pharma twist. Read More
